Compared with the DCM group, HLF treatment significantly decreased the level of MDA and increased the activity of SOD of heart especially in HLF medium and high dose treatment group (P < 0.05 versus DCM group). This evidence concerns the gene SOD1 and familial dilated cardiomyopathy.